OrthoPediatrics Corp. (KIDS)
- Previous Close
21.40 - Open
21.53 - Bid 22.01 x 100
- Ask 22.40 x 100
- Day's Range
21.53 - 23.02 - 52 Week Range
20.25 - 35.99 - Volume
252,542 - Avg. Volume
203,598 - Market Cap (intraday)
550.76M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-1.64 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.29
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
www.orthopediatrics.comRecent News: KIDS
View More
Performance Overview: KIDS
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KIDS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KIDS
View MoreValuation Measures
Market Cap
550.76M
Enterprise Value
555.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.50
Price/Book (mrq)
1.55
Enterprise Value/Revenue
2.71
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.47%
Return on Assets (ttm)
-4.05%
Return on Equity (ttm)
-10.34%
Revenue (ttm)
204.73M
Net Income Avi to Common (ttm)
-37.82M
Diluted EPS (ttm)
-1.64
Balance Sheet and Cash Flow
Total Cash (mrq)
68.83M
Total Debt/Equity (mrq)
22.82%
Levered Free Cash Flow (ttm)
-33.37M